诺华制药公司开发的依维莫司(商品名:Afinitor)于2012年7月20日获美国FDA批准,与依西美坦(商品名:Aromasin)联用于治疗激素受体阳性、HER2阴性的绝经后晚期乳腺癌患者。FDA药物评价和研究中心血液和肿瘤学产品办公室主任Richard Pazdur博士称,这是mTOR抑制剂类药物首次获准用于激素受体阳性的绝经后晚期乳 Novolin, developed by Novartis Pharmaceuticals, was approved by the U.S. FDA on July 20, 2012 and used in combination with exemestane (trade name: Aromasin) to treat hormone receptor-positive and HER2-negative Postmenopausal patients with advanced breast cancer. Dr. Richard Pazdur, director of the office of blood and oncology products at the FDA Center for Drug Evaluation and Research, said this is the first time a mTOR inhibitor has been approved for hormone receptor-positive late postmenopausal milk